Discovery To Commercialization: The Right Partnerships Are Key To Streamlined Drug Development

As of early 2024, nearly 12,500 drugs were in the preclinical phase of the R&D pipeline globally, up from 11,835 in 2023. More than 8,300 of these were in Phases I-III, an increase from 7,623 the previous year, while just under 300 were in pre-registration, compared to 250 in 2023. Although these increases are modest, they indicate growing activity within the pharmaceutical sector.

Simultaneously, the drug development landscape is continuously evolving, with emerging trends presenting new challenges for pharmaceutical companies. These trends affect all stages of development, from initial research to regulatory approval and commercialization. To navigate these challenges, companies increasingly rely on outsourcing and strategic partnerships with contract development and manufacturing organizations (CDMOs), which provide specialized expertise and help reduce development costs. There is also a growing focus on risk-based approaches and quality by design (QbD) to streamline development and tech transfer processes.

To maximize development success, selecting the right CDMO partner is crucial. A misalignment with a CDMO lacking the necessary support can lead to unnecessary delays, increased costs, and potentially jeopardize the entire project. This eBook serves as a comprehensive guide for pharmaceutical companies, outlining essential questions to consider when choosing the right CDMO partner for their unique projects, such as:

• What are the current trends in oral solid dosage and sterile product manufacturing?
• What benefits do outsourcing and strategic partnerships offer?
• How can companies select the right CDMO?
• Why is it important to partner with an integrated service provider?
• How can Alcami contribute to your project's success?
• What does the future hold for CDMO collaborations?